Streetbeat News

CSLLY

CSL Ltd.

https://www.csl.com/

CEO

Paul Perreault

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

78.99

Mkt cap

77B

Volume

5.3K

High

79.56

P/E Ratio

29.19

52-wk high

109.00

Low

78.82

Div yield

0.02

52-wk low

77.37

The European Commission has approved KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics. This vaccine shows superior immunogenicity and antibody persistence compared to conventional mRNA vaccines.

Portfolio Pulse from

February 14, 2025 | 1:45 pm

The European Commission has approved KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics. This marks the first approval of its kind by the EC.

Portfolio Pulse from

February 14, 2025 | 1:15 pm

CSL Limited (CSLLY) held its Q2 2025 earnings call, discussing financial results and company updates. Key participants included executives from CSL and analysts from major financial institutions.

Portfolio Pulse from

February 11, 2025 | 1:45 pm

CSL Behring's gene therapy HEMGENIX shows sustained efficacy and safety in treating hemophilia B, with 94% of patients eliminating factor IX prophylaxis and maintaining near-normal factor IX levels four years post-treatment.

Portfolio Pulse from

February 07, 2025 | 2:30 pm

The article highlights three high-dividend yielding healthcare stocks: Gilead Sciences, GSK, and AbbVie. Analysts have provided ratings and price targets for these stocks, with recent news impacting each. Gilead has a licensing agreement with Dr. Reddy's, GSK received U.S. government funding for bird flu vaccines, and AbbVie is set to announce its Q3 financial results.

Portfolio Pulse from Avi Kapoor

October 07, 2024 | 11:19 am

The U.S. government has allocated $72 million to GSK, Sanofi, and CSL to increase bird flu vaccine production. This funding aims to double the U.S. supply of vaccines, with a target of 10 million doses by early 2025. The companies will produce extra vaccine components and ensure a steady supply of traditional flu vaccines.

Portfolio Pulse from Vandana Singh

October 04, 2024 | 4:31 pm

The U.S. HHS is awarding $72 million in new grants for bird flu vaccine manufacturing to companies including Sanofi, GSK, and CSL. The CDC has confirmed two new human cases of bird flu in California, prompting symptom monitoring on affected dairy farms.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:09 pm

Arcturus Therapeutics and CSL Limited's COVID-19 vaccine, ARCT-154, demonstrated superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, even at lower doses. The vaccine showed better antibody responses against various COVID-19 variants, including Omicron, over a year. ARCT-2301, another vaccine from the same platform, also outperformed Comirnaty in inducing neutralizing antibodies.

Portfolio Pulse from Vandana Singh

September 30, 2024 | 3:12 pm

The US Department of Health and Human Services (HHS) announced that eight laboratories have signed royalty-free agreements for H5N1 tests. Moderna has a deal that allows it to pivot to other pandemic threats, though it's too early to determine its vaccine production capacity. The first H5N1 vaccines from CSL Seqirus are expected to be ready by mid-July.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 2:58 pm

CSL and Arcturus Therapeutics announced that Nature Communications has published pivotal data demonstrating the efficacy and tolerability of their self-amplifying (sa-mRNA) COVID-19 vaccine, ARCT-154. The data shows superior immunogenicity to Omicron BA 4/5 and longer duration of immunity compared to traditional mRNA COVID-19 vaccine boosters.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:42 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.